← All trials
NCT04290572
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2020
- Primary completion
- Feb 28, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 2, 2020
- Last posted
- Mar 3, 2020
- Enrollment
- 162
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centro Dermatológico Dr. Ladislao de la PascuaLead sponsor
- Centro Dermatológico Dr. Ladislao de la PascuaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.